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Abstract
The number of paediatric clinical trials in EU has remarkably increased in the last decade 
in response to the implementation of the new Paediatric Regulation and incentives aim-
ing to define the need of child-specific drug development. Nevertheless, the gap between 
the number of paediatric and adult-randomised controlled trials is still substantial in 
almost every major clinical specialty. Economic, ethical, technological, geographical and 
cultural factors can influence the paediatric drug development and can represent the 
challenges to be faced for a smooth conduction of a paediatric clinical trial. The need 
for trials and paediatric patient’s engagement to commensurate with the approved pae-
diatric investigation plans is so high that it is crucial to correctly address key factors. 
Particular care should be taken to develop well-designed studies, with efficient man-
agement plans, experienced administrative and healthcare personnel, awareness of 
socio-cultural features of the geographic areas involved and good communication with 
patients and their families in order to ensure ‘trial preparedness’. A case study on a mul-
tinational paediatric clinical trial, presented within the recently ended research project 
‘DEferiprone Evaluation in Paediatrics (DEEP)’, was reported to exemplify some of the 
challenges encountered by the authors and the actions taken to overcome them.
Keywords: paediatric clinical trial, children medicines development, clinical trial 
management, ethics, patient enrolment, trial preparedness, drug formulation, 
regulatory, patient engagement
1. Introduction
Paediatric clinical research was introduced in response to the increasing gaining of awareness 
that paediatric subjects cannot simplistically be defined as ‘small-scale’ adults but that possess 
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a unique and constantly evolving set of physiological, mental and metabolic characteristics 
that require a dedicated exploration to identify their appropriate needs.
Before the introduction of international regulations and incentives aiming to define the need of 
child-specific drug development, paediatric subjects were systematically given off-label treat-
ments, which did not possess any efficacy or safety data for their specific population but that 
were only tested in adults. The reason for this lack of interest lies on a lower market appeal, 
together with the fact that the design and execution of clinical trials in children have always been 
on one hand a controversial matter, with very delicate ethical implications to be considered and 
consequently regulated, and on the other hand a difficult process, with low number of patients, 
intrinsically fragmented in further subgroups and with a need of tailored formulations.
2. Historical perspectives
The milestone that signed the beginning of the modern paediatric clinical research, with care in 
defining the proper requirements and ethical issues related to this vulnerable population, was 
represented by the introduction of the first international regulations on paediatric subjects.
These regulations have been defined independently in the most developed countries, but in 
accordance to unified guidelines suggested by the ICH, an organization working on the har-
monization of pharmaceutical regulatory requirements within the EU, Japan and the USA.
2.1. Definition of paediatric population
Defining the paediatric population is a very complex task, as it encloses a very broad and 
multifaced spectrum of subjects. The international regulation on paediatric clinical trials [1] 
has subdivided it in further four subsets: pre-term and term neonates (0–27 days), infants 
(1–23 months), children (2–11 years) and adolescents (12–18 years). According to the recently 
revised EMA guideline ‘Ethical considerations for clinical trials on medicinal products con-
ducted with minors’ issued on September 2017, the age groups of children and adolescents 
have been further redefined into pre-schoolers (2–5 years), schoolers (6–9 years) and adoles-
cents (10–18 years) [2]. The latter age group is based on the WHO definition of adolescence 
starting at the age of 10 years but maybe it has to be further subdivided into two subgroups 
because it seems to the authors to be too wide. Age groups can be differently subdivided, and 
often these categories are only used to provide guidance for regulatory and clinical reasons but 
do not reflect the maturity of the individuals, which is something that is generally recognized 
as crucial aspect to be taken into account during the conduct of paediatric clinical trials. Given 
these uniqueness, nonetheless, international paediatric regulations try to create a unified sys-
tem of rules and laws, aiming to define the needs and protect the entire paediatric population.
2.2. European Paediatric Regulation
The European Paediatric Regulation was adopted in 2006 and entered into force in 2007. It 
‘lays down rules concerning the development of medicinal products for human use in order 
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to meet the specific therapeutic need of the paediatric population, without subjecting the pae-
diatric population to unnecessary clinical or other trials and in compliance with Directive 
2001/20/EC’ ([3], Article 1).
Since its implementation, the Paediatric Regulation has a very positive impact on paediatric 
drug development. The 10-year report of the EMA has shown that it has led to more medi-
cines for children, better and more information for prescribers and patients, better paediatric 
research and development, more regulatory support for paediatric matters and paediatrics 
now being an integral part of medicine development [4].
Main sections ruled by the Regulation are:
• the institution of the PDCO;
• the definition of the regulatory requirement for a marketing authorization, among which 
the PIP;
• the introduction of rewards and incentives for the development of paediatric drugs, i.e., the 
PUMA.
2.2.1. PDCO
The Paediatric Committee is composed of independent and impartial members appointed 
from Member States, health professionals, and patients’ associations. In its whole, the PDCO 
provides scientific competences on the main areas of the paediatric medicines, such as drug 
development, paediatric medicine, physics, paediatric pharmacology, pharmacovigilance, 
ethics and public health. Its main roles are:
• to assess and give a final opinion on the content and compliance of PIPs, waivers and 
deferrals;
• to give advice on issues related to surveys on the use of medicinal products in paediatric 
patients, to the establishment of a European network for paediatric research (EnprEMA) 
and to the elaboration of documents related to the Regulation;
• to establish a specific and updated inventory of paediatric medicinal product needs.
2.2.2. PIP
The Paediatric Investigation Plan is a document that describes timing and measures by 
which the developer of an IMP proposes the assessment of quality, safety and efficacy of 
that IMP in all the concerned subsets of paediatric population, giving also indications of the 
measures to be taken to adapt the formulation of the product to the needs of each paediatric 
population. It must be drawn up and submitted to the PDCO at the EMA with a request of 
agreement before any application for marketing authorisation and possibly not later than 
upon completion of the human pharmacokinetic studies in adults. The PDCO is in charge 
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of the assessment of the PIP and may request further clarifications and modifications to the 
applicant. The final opinion can be either positive or negative.
The developer will be granted a waiver, if:
• the IMP and the proposed plan are judged unsafe or ineffective in some subset or in the 
whole paediatric population;
• the IMP does not represent a significant therapeutic benefit over other existing treatments 
for paediatric patients.
2.2.3. PUMA
The Paediatric Use Marketing Authorisation is a marketing authorisation that gives sup-
plementary protection to a medicinal product for human use exclusively developed for its 
indication/formulation for paediatric use, where this same medicinal product was already 
authorized and is not covered anymore by a patent. It is granted to IMPs that have success-
fully completed an agreed PIP and have set a risk management plan for the follow-up of effi-
cacy and safety of the product. It warrants data and market protection for 10 years.
2.3. American Paediatric Regulations
Paediatric clinical research started in the US few years in advance compared to Europe. The 
most recent legislation ruling this subject is essentially enclosed in two main acts, i.e., the 
PREA, also known as ‘the paediatric rule’ of 2003 [5] and the BPCA, ‘paediatric exclusivity’ of 
2002 [6], both amended in the FDAAA of 2007 [7].
2.3.1. PREA
The Paediatric Research Equity Act defines the regulations on the subject of research into 
paediatric uses for drugs and biological products. The organ assigned to the assessment 
and supervision of the paediatric drug development is the Secretary of Health and Human 
Services, which acts in collaboration with a designated internal committee within the FDA 
with expertise in paediatrics, biopharmacology, statistics, chemistry, legal issues, paediatric 
ethics, and appropriate expertise on the products under assessment.
They assess and review application on drugs for paediatric use and are entitled to grant 
approvals or, in well justified cases, deferrals for the performance of the study in paediatric 
patients, or even waivers for products not suitable for children or in which the performance 
of the study is proven highly impracticable. The cases in which the disease and the effects 
of the drug are similar enough in adults and paediatric patients, an opinion can be issued 
in which paediatric effectiveness will be extrapolated from well-designed studies in adult 
patients, maybe with the addition of supplementary data obtained in paediatric subjects such 
as pharmacokinetics studies.
In addition, the PREA highlights the necessity of a transparent public dissemination of pae-
diatric data obtained either from new products or from marketed drugs for use in adults. It 
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is also duty of the secretary to perform periodic surveys and reviews, analyse data and create 
statistics on paediatric studies in terms of number of assessments, authorizations, waivers 
and deferrals, paediatric plans and timelines, formulations, labelling changes and recommen-
dations and report them to the Congress. The suggested channel for the public dissemination 
of data is the FDA website ([7], title IV).
2.3.2. BPCA
The Best Pharmaceutical for Children Act establishes an incentive system for the performance 
of paediatric studies with the aim of expanding the number of labels, indications and safety 
and efficacy information in the different paediatric subgroups. In this case, when the secretary 
judges that information related to the use of a new drug or an already-marketed drug in the 
paediatric population would be beneficial on public health, it issues a written request to the 
sponsor, that for completing such study in a defined timeframe and providing the informa-
tion requested will be granted an extension of 6 months on market exclusivity ([7], title VI). 
The BPCA can be considered one of the most successful legislative initiatives, which brought a 
huge increase in the paediatric studies and the subsequent assignment of paediatric labelling.
3. Challenges in paediatric drug development
Paediatric drug development is hampered by many factors that historically have made it a 
neglected subject in the pharmaceutical industry’s scenario. These factors are of different 
nature and altogether contribute to the challenge that a sponsor has to face in order to per-
form and complete a PCT. This section describes these main challenging factors, as a practical 
overview of the crucial aspects to be considered before the initiation of a PCT, in a perspective 
of “trial preparedness” (also categorized in Figure 1).
3.1. Economic burdens
Drug development is a long, extremely expensive process, with low percentages of success, 
i.e., final market authorization. The last decades have seen an intensification of the economic 
challenges, with R&D costs constantly increasing and successfully commercialized products 
regularly decreasing. In the paediatric research, the economic factor represents a big barrier, 
as the returns promised by the paediatric market are even more disadvantageous compared 
to the burden that has to be undertaken. Crucial factors that make paediatric investigation 
economically more challenging and therefore less profitable are as follows:
• small patient population, which is further fractioned in several subgroups and strongly 
reduces market’s size;
• under-developed infrastructures, which undermine a timely and cost-effective perfor-
mance of PCTs, i.e., properly GCP-trained paediatric investigators, investigation sites, 
centralized laboratories and contract research organizations with specific expertise in 
 paediatric trials;
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Figure 1. Aspects to consider for trial design. The flowchart summarises the most common drawbacks that can be 
encountered during the conduct of a paediatric clinical trial.
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• need of age-appropriate formulations, that are often very difficult to develop because of 
the chemical-physical characteristics of the active moieties, the possible adverse reactions 
of the excipients, the taste, total volume etc. This process is therefore very challenging on 
a technical point of view, taking long time to complete and making the cost/profit ratio of 
the drug disadvantageous;
• risks in children can be higher than in adults, with unpredictable serious adverse reactions 
and long-term effects. These risks may result in pecuniary liability, which represents a 
strong deterrent for all the parties involved, i.e. sponsors, producers, all levels of healthcare 
as well as liability insurers.
3.2. Drug formulation
The technological development of a drug for paediatric use is very demanding, and it has to 
take into consideration many aspects that could be of potential harm for minors or act as a 
deterrent for a correct and continued administration of the treatment. Therefore, many guide-
lines have been disseminated by EMA and WHO [8–11] that identify acceptable paediatric 
drugs’ features in terms of quality and formulation.
3.2.1. Drug quality
This aspect is of high importance if we consider the fact that children can be more susceptible 
to chemicals and bioactive substances, hence it is crucial that the composition of the drug 
is well known and characterized. ICH provides several guidelines regarding the limits for 
potentially harmful chemicals to be found in API in the form of impurities, degradation prod-
ucts and solvent residuals [12–15]. These limits apply for both adults and children, with the 
idea that less quantity will be administered to children. Most of the times, drugs to be used 
in the younger children’s subgroups, i.e., neonates, toddlers, infant and young kids, need 
further attention, as they require preclinical studies to be performed first on juvenile animals 
in order to assess possible short- and long-term toxicities, thus increasing the time spent on 
the final formulation of the drug.
3.2.2. Excipients
According to the working document on paediatric medicines development of the WHO, for 
the choice of excipients to be used for a paediatric formulation, there should be a consid-
eration on different aspects, e.g., the safety in the target age group, based on the route of 
administration and the frequency, duration and dosage of treatment [10]. The risks are higher 
for liquid formulations, but in general, the number of excipients used for a paediatric formu-
lation should be kept to a minimum, as safety data in younger children are mostly limited if 
not totally missing. Colouring agents and antimicrobial preservatives have quite often toxic 
and allergenic potential and should be avoided as far as possible, e.g., favouring solid for-
mulations to the liquid ones. This last solution has however negative consequences on the 
appropriateness of intake by younger children, as they could badly accept them due to the 
inability to swallow tablets. Sweetening agents are another delicate aspect. On one hand, they 
are often required in liquid formulations to mask an otherwise unpleasant taste of the drug 
that could compromise the adequate administration and intake of the treatment. On the other 
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hand, sweeteners’ possible side effects should be kept in consideration, i.e., cariogenicity, 
laxative effects, glycaemic spikes in patients with diabetes, inflammatory reactions in patients 
with fructose intolerance, etc.
3.2.3. Dosage forms
Strength and dosage forms of paediatric drugs are important aspects to ensure a precise and 
manageable administration of treatment. Ideal formulation should warrant a ready-to-use 
shape, ideally adjusted on an age-specific need base, meaning more than one dosage form or 
more than one strength of a dosage form of the API. A minimal dosing frequency should be 
attempted, therefore favouring prolonged-release to immediate release formulations.
3.3. Trial design
The phase of planning is the most crucial for the smooth and prompt conduct of a clinical trial. 
Therefore, it requires a consistent amount of groundwork, logical thinking and awareness of 
the possible risks and complications. This can be even more true in the case of PCT, where the 
sensible factors to be considered are usually many more and more difficult to solve than for 
the clinical trials to be performed in adults.
3.3.1. Innovative trial design
Notwithstanding their little spread in the common use, innovative trial design methods are 
particularly suitable and powerful for facing issues related to low patients’ number and con-
trol groups of PCTs. Bayesian design allows the extrapolation of results out of fewer children 
than in the conventional, fixed-number design, also considering evidences on adults [16]. The 
randomised withdrawal approach is mostly appropriate for long-term illnesses. More innova-
tive trial design methods are being developed, thanks to the use of simulation studies. These 
methods, thanks to their features, represent a reliable way of ultimately improving paediatric 
care, by sensibly limiting the number of children required for achieving good-quality and 
ethical research [17].
3.3.2. The patient’s perspective
It is crucial for clinical trial success to design a study with deep consideration of the patients’ 
needs and perspective, such the possible pain or discomfort caused by certain invasive pro-
cedures or by interventions during a particularly difficult status of the patient, the length of 
assessments and interviews, the number of visits, the duration of the study and the frequency 
of drug intake. Not least, consideration should be given to the delicate aspect of data protec-
tion within the category of vulnerable subjects, which minors belong to.
3.3.3. Quali-quantitative assessments
Another obstacle that requires lots of problem-solving capacity in the design of a PCT is 
the lack of tools and/or methods for quantitative and qualitative assessment tailored for the 
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 paediatric population and its subgroups. Examples in which these deficiencies can be found 
are as follows:
• study endpoints;
• questionnaires and scales for the measurement of psychophysical parameters;
• tools for the assessment of adverse reactions.
The use of scales and tools validated for the analysed patients’ age is crucial to guarantee the 
proper collection and value of data for a trial. Lack of these means can imply the impossibility 
to proceed with a certain endpoint, thus invalidating the study.
3.3.4. Biological specimens
Many trials require the collection of patient’s biological samples for the acquisition of crucial 
data. The aspect of the blood withdrawal in particular has to be carefully evaluated. On an 
ethical point of view, there is the need of avoiding as much as possible any kind of discomfort 
or pain to the child. On a clinical point of view, there is a very limited volume of blood (and 
other biological samples) that can be drawn from a child [18]. A document of recommenda-
tions, produced in 2008 and recently revised by the ad hoc group for the development of 
implementing guidelines for Directive 2001/20/EC, states that trial-related blood loss should 
exceed neither 3% total blood volume during a period of 4 weeks nor 1% at any single time 
[2]. These considerations have to be carefully implemented during trial design, as it can be a 
reason for rejection by the ethics committee evaluating study regulatory submission.
3.4. Regulatory process
The procedures and times for regulatory approvals in different countries and investigation 
sites can be very inhomogeneous and time-consuming. Each regulatory body requires a sepa-
rate process of revision, with comments to be addressed separately. This process is a big 
drawback in the case of multi-centre international studies, because it could generate differ-
ent versions of the study protocol that will have to go through a further step of amendment 
in order to be harmonized among the investigation sites. In the European context, the new 
Regulation on Clinical Trials foresees the implementation of a centralized system of submis-
sions to speed up and harmonize the process of regulatory approval of clinical studies within 
EU [19]. When active, this system will allow a single, fully electronic submission through 
the EU portal for all the Member States concerned. Technical and scientific aspects of the 
trial application will be discussed jointly, whereas ethical aspects will be appraised sepa-
rately by the concerned Member States. They will give back opinions and requests of clarifica-
tion following unified deadlines. Each Member State will then give an individual response 
to the sponsor through the EMA portal. In conclusion, the centralized submission will be 
followed by separate authorizations. Studies’ information will be then accessible through a 
unified European database. In preparation to the implementation of this new system, a sort 
of test version has been introduced in the last few years by the EMA with the VHP, which 
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already allows a much smoother process for study approval in European investigation sites. 
Nonetheless, the system still needs to be followed by submissions in single countries, and 
country-specific requirements are still present.
3.5. Ethical issues
Paediatric clinical research has multiple ethical implications that represent a big component 
in the difficult process of performing paediatric clinical trials.
These implications are the centre of all the regulations that have been implemented on this 
matter, and still some grey areas persist and are under constant improvement and implemen-
tation. Nevertheless, ethical principles have been expressed in lots of documents produced by 
the most influential organizations worldwide, such as WHO, ICH and EMA [2, 20–23]. Major 
points are that children should not be subjects of clinical trials when the research can be per-
formed in less vulnerable populations, and if the research is necessary, care should be taken 
to include first the least vulnerable subgroups. Unnecessary replication of trials in children is 
considered unethical too.
More generally, PCTs should be conducted following the so-called ‘Belmont principles’, which 
are beneficence (do good and avoid harm), justice (fair distribution of burden and benefits of 
research) and respect to persons [24], and the four healthcare ethics’ principles of autonomy 
(rights of patients to take decisions about their medical treatment), beneficence and non-malefi-
cence (called just beneficence in the Belmont principle) and justice [25].
3.5.1. Informed consent and assent for paediatric groups
The issue of the informed consent in PCTs is very delicate because, on a legal perspective, 
children cannot provide a consent for themselves. For patients under legal age, informed con-
sent has to be given by the parent(s) or a legal representative. According to the several com-
mon guidelines valid within the EU [2, 26], informed consent must be given before patient’s 
enrolment in the trial, and after receiving an adequate information on the purpose of the 
research, potential risks and benefits related to the involvement of children in the clinical trial, 
randomization, volunteering nature of the enrolment and absolute freedom to withdraw any-
time with no consequences. This information must be provided by experienced investigators, 
putting no pressure whatsoever and allowing enough time for the parents/legal representa-
tive to reflect on it and ask for further information if needed. Communication must be very 
clear, and the comprehension of the information must be ensured even with the assistance 
of a mediator if necessary. Informative material must be therefore very clear, complete and 
easy to read, which is very much valued by ethics committees appraising PCT applications. 
Children able to a certain degree of understanding of the research should be, as an important 
principle of ethical research, involved in the process of making decisions about the enrolment 
in a trial. This involvement must take into consideration the maturity level of the child, so the 
communication and the informative material prepared must be age appropriate (this aspect 
is another very important step in the ethics committee evaluation process). The information 
can be followed by the obtainment of an assent from the child. In general, both consent and 
assent must be checked by the investigator as part of the normal communication with parents 
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and children for the entire period of the trial. Informed consent must be sought again as soon 
as possible where a paediatric patient is no longer a minor.
However, despite internationally accepted ethical principles and the EU guidelines, special 
provisions for children vary between and, in some cases, within countries due to differences in 
national laws and practices. A unique definition of legal age of consent is lacking, and the valid-
ity of assent and age-grouping is therefore not harmonized across Europe. As the EnprEMA 
marked in the paper ‘Informed consent for paediatric clinical trials in Europe’, usually the 
legal age for the informed consent is 18 years, but it differs in some countries: in Austria, it 
is 14; in Finland and Denmark, it is 15; and in the UK, it is 16 [27]. Specific characteristics in 
terms of informative material to be provided as well as requirements on the matter of rights 
of the patient to sign informed consent or assent, whether in addition or not to the parent’s 
consent are detected [27, 28]. Solving this issue is of primary importance in the perspective of 
implementing the new European Regulation, since the lack of EC practice harmonization will 
impede the achievement of a unified evaluation of PCT applications at central level.
3.5.2. Data protection and biological samples retention
The major concern about data protection in children regards their possible uses in the future, 
after the termination of a trial. In this matter personal information are included, in particular 
regarding sexuality or illicit substance abuse, but also biological samples collected and stored 
long-term. There is the need of a careful protection of these data. Retention of any material must 
be consented (and reconsented once the child comes of age) and confidentiality guaranteed.
3.5.3. Discomfort and distress in trial procedures
Given the vulnerable nature of paediatric patients, extra attention must be paid to the discom-
fort or pain caused to children by trial-related procedures. This is a very important ethical issue 
that has to be widely considered when designing a PCT, to take all the measures to avoid unnec-
essary distress in every feasible way. In any case, signs of discomfort, pain and distress must be 
always measured through the use of validated age-appropriate scales. Appropriate analgesia 
should be provided where a certain degree of pain is caused by strictly necessary procedures.
3.5.4. Insurance
Insurance is compulsory in order to safeguard patients. In the case of PCTs, it is important to 
make sure that insurance includes long-term liability. Since this risk is much higher in chil-
dren than in clinical trials performed in adults, insurance companies are reluctant to provide 
this protection. Finding the right company can be therefore quite a challenging process in the 
start-up of a PCT.
3.5.5. Safety
As in every clinical trial, safety must be constantly evaluated and monitored, and adverse 
events should be always timely reported. Safety in paediatric subjects, given their vulner-
ability, is very important, but detecting these events can be particularly complicated. First, 
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because children could show effects never seen before in adults, with the consequence of 
unpredictable manifestations. Second, because especially in neonates and toddlers, the reac-
tion could not be easily detectable, and they do not have the possibility to communicate their 
symptoms. Third, because some methods for detection of adverse reactions are not validated 
in children, making this assessment hard and imprecise. Consequence of this issue can be on 
one hand the missed detection of an adverse reaction or on the other hand (more common) 
the over-interpretation of symptoms as adverse events and the subsequent withdrawal of 
patients from studies, contributing to issue of patients’ retention.
3.6. Patients enrolment and retention
The problem of low percentages in patients’ enrolment and retention in PCTs is an issue that 
contributes to the failure in reaching the numbers for proper study’s completion [29] and there-
fore has probably the biggest impact on the way a PCT is designed. There is a paucity of eligible 
paediatric subjects for the majority of studies that is dependent on epidemiologic reasons but 
also on a high degree of patients withdrawing from the studies as well as patients’ families 
being wary about clinical trial’s possible risks. This shortage of patients has to be compensated 
in most of the cases with the involvement of multiple investigation sites. This choice though is 
often a double-edged weapon, because on one hand, it improves the chances to reach the mini-
mum number of patients necessary to successfully complete a study, and on the other hand, 
it substantially extends the time, work and costs required for the obtainment of regulatory 
approvals to conduct the studies in different sites and/or countries and for the study conduct.
3.6.1. Communication with patients and families
Many reasons can be identified for the scarce rate of patient’s recruitment and retention in 
PCTs, among which the wrong approach or miscommunication with patients and their fami-
lies. The wrong communication between the clinical staff and patients can be tremendously 
detrimental, because it can lead to the participant (or potential participant) and his family not 
understanding correctly the conditions of the study, its aims, benefits and potential risks. They 
could feel distrustful if the entire process is not explained in a transparent way, or even threat-
ened, if they don’t understand correctly the important concept of voluntary participation.
In 2012, following a large consultation phase, the PDCO issued a Concept Paper on the 
involvement of children and young people in its activities, with the children’s best interests 
as primary consideration [30]. The setup of a child-friendly approach implies a collaborative 
and continuous action involving paediatricians and healthcare professionals, psychologists, 
families, and patients. Children and parents should be involved not only in the daily clinical 
practice but also in the whole study development, revision of clinical study protocols and use 
of drugs. Healthcare professionals should consider children and families’ active participation 
as a fundamental step to reach consensus and compliance to treatments and to increment 
patient’s enrolment and retention. Furthermore, it is necessary to recognize that a standard 
model of information is not valid for all age groups; therefore, in addition to parents, children, 
adolescent and mature minors should receive information in a clear and understandable way 
for their level of comprehension and maturity. These concepts are clearly underlined also in 
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the consultation document ‘Ethical considerations for clinical trials on medicinal products 
conducted with minors’, recently updated to be in line with the new Clinical Trials Regulation 
536/2014 [2].
3.6.2. Patients’ withdrawal
Many factors that could cause discomfort or be uneasy to be pursued by patients or their 
families have been related to patient’s withdrawal. Most common reasons for withdrawing 
a paediatric study are the wrong formulation of the drug, i.e., the taste (too bitter or with a 
taste that does not match the preferences of the population the drug is used on), the pharma-
ceutical form (tablets, capsules, difficult to swallow for some patient’s subgroups or injectable 
solutions that require assistance and could preclude a normal life for the patient) and the 
strength (not easily scalable for smaller children). Too many doses of treatment per day can 
cause withdrawal as well or increase the risk of lack of adherence to the study protocol. Too 
many hospital visits plus the lack of any form of compensation for the expenses can represent 
a strong deterrent for parents that have to give up on work days. Distressful procedures such 
as frequent blood withdrawals should be avoided as well.
3.7. Multicentre international studies
As discussed in Section 2.6, the need to increase the number of paediatric patients enrolled in 
a study in order to reach an adequate statistical sample, is usually managed with the design 
of multi-centre studies, often performed in different countries as well. This type of trials has 
in its turn other problematic consequences.
3.7.1. Time and costs
Performing a trial in multiple locations means that the work will be multiplied. There is the 
need to localize and make agreements with many structures that comply with all the require-
ments of the study. The study must be approved by multiple competent authorities and ethics 
committees that can ask for different clarifications, and this can lead to different versions of 
the study protocol. Submission packages for these requests of authorization must be tailored 
from country to country, documents for patients such as informative documents, consent and 
assent forms, but also labels and protocol synopsis have to be translated in the local languages. 
Substantial differences in the version of study protocol and documents, consequence of the dis-
cussion with the different local CAs and ECs, will probably lead to the necessity of an amend-
ment that implements in one version all the edits and makes a right compromise with all the 
requirements to be submitted again to all the regulatory bodies for approval. If in some cases, 
a compromise is not possible because of unconcealable ethical principles, different versions 
have to be handled provided that the aims and GCP compliance of the study are not affected.
3.7.2. Geographic differences
The conduct of the study could be also affected by geographic issues from country to country, 
especially in locations outside the EU.
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Cultural and social differences will cause a very different process of review of the clinical 
trial application by the ECs that will point out different ethical aspects also depending on the 
common sense in their society, filtered by cultural, religious and/or political biases. IMP’s 
formulations could be inappropriate for certain populations, as regards taste, pharmaceutical 
form and/or storing conditions. Border policies could hinder the proper exchange of biologi-
cal material, IMP, as well as study-specific equipment. Finding the right compromise with 
all the different countries’ requirements and needs in order to keep a well-coordinated study 
planning and conduct could be therefore very demanding.
4. Overcoming different issues: a case study on a multicentre 
multinational PCT
As discussed in the previous section, the performance of a PCT is fulfilled with many obsta-
cles that can compromise its success and final outcome. Good strategy, problem solving and 
a wide preliminary research and awareness of the issues that could present can improve the 
chances to successfully complete the study. In this section, we propose some solutions for 
the issues described above, and we use as example the case study of a recently performed 
research project, the DEEP. DEEP is a 6-year European Project (FP7) coordinated by Consorzio 
per Valutazioni Biologiche e Farmacologiche (CVBF), a non-profit research consortium based 
in Italy, comprising 23 recruiting centres in European and non-European countries, scientific 
partners from several European countries and a pharmaceutical group based in Canada. The 
DEEP Project has the specific aim to produce a new oral liquid formulation of deferiprone 
suitable for paediatric use and to integrate the existing information on deferiprone use in iron-
overloaded paediatric patients. It consisted of three studies, DEEP-1, DEEP-2 and DEEP-3 in 
accordance with the PIP submitted to the EMA-PDCO in February 2011 and amended and 
finally approved in November 2011. It is to be mentioned that the PIP has undergone several 
modifications upon PDCO request: the age of patients to be recruited, which was extended 
including all the paediatric ages (from 1 month to 17 years instead of the previously proposed 
2–10 years), the sample size (from 240 patients to 310) and also the comparator (from deferox-
amine to the more expensive deferasirox), with a huge increase of time and cost.
The DEEP-1 was a multi-centre, oral single dose experimental and modelling study to evaluate 
the pharmacokinetics of deferiprone in patients under 6 years of age affected by transfusion-
dependent haemoglobinopathies (NCT01740713, clinicaltrials.gov). It was concluded in 2014, pro-
viding scientific evidence that the dosage per kilogram of deferiprone used in adults and older 
children can provide sufficient exposure to ensure efficacy also in younger children. These results 
allowed children aged under 6 years to start to be recruited in DEEP-2 Safety/Efficacy Study.
The DEEP-2 was a phase III multicentre, randomised, open label, non-inferiority active-con-
trolled trial aiming at comparing the efficacy, in terms of changes of serum ferritin levels 
and cardiac iron overload, of deferiprone versus deferasirox in paediatric patients affected by 
hereditary haemoglobinopathies, requiring chronic transfusions and chelation (NCT01825512, 
clinicaltrials.gov). It has involved 393 randomized patients with the FPFV in January 2015 and 
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LPLV in September 2017. The DEEP-3 was a long-term observational safety study which eval-
uated the nature and incidence of adverse effects of deferiprone in children and adolescents 
with beta-thalassaemia major. Started in 2013, and ended in October 2015, with 297 patients 
enrolled in the study, it confirmed that the safety profile of deferiprone in children and ado-
lescents is in accordance with the available data in adults.
4.1. Regulatory
The process for granting regulatory authorization in a multicentre multinational PCT is a big 
time-consuming factor. Every step (submission of PIP, study approval from CAs of every 
country and from ECs that can be country-specific or even local for the single centres as it is 
in Italy) can require several months to be completed. In addition, the legal approach is dif-
ferent among countries: each of them has its own rules governing the submission of CTs. On 
average, a large part of the regulatory bodies involved in the approval process asks for clarifi-
cations and/or changes regarding the study protocol, informative material, etc. In the case of 
DEEP-2, several issues raised on this topic.
In Tunisia, where trials on non-marketed drugs were not allowed on minors, a special authori-
sation from the Ministry of Health had to be granted before ECs could approve the study. In 
Albania, a national Law on clinical trials was absent until July 2014; therefore, it was much 
harder to obtain regulatory approval there. In Egypt, despite several requests, biological sam-
ples’ exportation for the centralized analyses was never authorized. In Cyprus, the eligibility 
of patients under 2 years of age was denied, notwithstanding the European regulation, since 
the study had already been approved in other European countries. For all these obstacles, it 
was crucial to have a dedicated regulatory team and to have appointed an external expert 
Ethics Board that could rapidly deal with all the actions required and solve correlated issues.
4.1.1. Ethics and safety
Since ethical and safety issues are among the major concerns in PCTs, in order to ensure a 
good quality conduct of the study, with focus on the safety and wellbeing of the paediatric 
patients, a DSMC and an EB were established for DEEP-2 study. The DSMC’s main responsi-
bility was to ensure safety monitoring of patients and quality of statistical methods, whereas 
EB revised the essential documents and procedures dealing with ethical aspects such as (but 
not limited to) documents for the ECs, Consent and Assent Forms, protocols, results and 
reports from the studies. In particular, it suggested interventions aimed to protect children’s 
well-being both in the European and non-European Countries, and the use of studies results 
in favour of the affected populations. In addition, the EB worked in collaboration with the 
DSMC on all aspects of data protection and confidentiality.
4.1.2. Extra-European studies
For studies outside Europe, national legislations in matter of clinical trials are still very differ-
ent, and cultural and social diversity affects a lot the common sense of ethics. This issue was 
faced in the DEEP-2 study. Actions taken to ease the management of the trial started from the 
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planning of the study. An initial survey was performed to define the legal framework regulat-
ing clinical trials in different countries. SOPs were setup and followed to implement a unique 
procedure and a unique CTA ‘package of documents’. Local CROs were employed that had 
the proper expertise together with the right awareness of socio-cultural and regulatory pecu-
liarities, as well as linguistic fluency. Majority of integrations were asked by the different 
ethics committees regarding the content of the informed consents and assents, and one of the 
most controversial and dependent on country-specific cultural influences was the topic of 
contraception and pregnancy (informative documents for Egyptian female adolescents could 
not include information regarding contraception, whereas for Greek patients, the insurance 
had to cover foetus damages even though contraceptive measures were explicitly mentioned 
in the informed consent form).
4.2. Patient-oriented perspective
On the base of the ethical principles concerning patient’s proper information and engage-
ment [2, 30], age-tailored (<6, 7–11, 12–17) information booklets explaining CTs’ aims and 
procedures and what they are going to experience, and assent forms were prepared in the 
framework of the DEEP-2 study. They were the result of a collaborative effort between phar-
macologists, paediatricians, child psychologists, communicators and illustrators. Their aim 
was to inform the participant child on the study’s objectives and procedures and to obtain his/
her assent to participate in the study. They were translated in all the six languages of the clini-
cal sites included in the trial (Albanian, Arabic, English, French, Greek, Italian). Furthermore 
patients, parents and patients’ organisations were involved in creating the protocol informa-
tion package, actively participating in the revision of documents for the children and contrib-
uting in the design of the dissemination strategy.
The educational part of the study towards kids and families is very important for the partici-
pation and compliance; another aspect that would be beneficial, and thus it would be worthy 
to contemplate it in a study, is the communication to patients and families of the trial results. 
In this regard, in the context of the DEEP-2 study, strong importance will be given to the 
establishment of an adequate form of communication of the results specifically designed for 
laypersons, meaning that comprehension can be reached and further transmitted by involved 
subjects and their families. The main principles of the lay communication will be followed, 
with the design of a summary that can be understood by an audience from the age of 12 years 
upwards. A child-friendly version of the lay summary will also be prepared to help younger 
children in understanding trial results.
4.3. Selection of centres
As discussed above, the choice of investigation centres can have a huge impact on the out-
come of a PCT. A careful selection of the centres involved in the DEEP-2 study was aimed to 
involve centres complying with as many of the following criteria as possible:
• being localized in a geographical area where epidemiology of the disease under study is 
high, and thus many patients can be approached;
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• availability of a Principal Investigator that has a relevant experience in GCP and PCTs, and 
is willing to collaborate with a proactive attitude;
• facilities necessary to perform all the diagnostics and procedures required by the study 
protocol present within the hospital/clinic;
• social and cultural features of the area in which the centre is located likely to allow a good 
understanding and acceptance of the study and of its requirements and characteristics.
4.4. Quality assurance
As already extensively discussed, the number of patients in PCT is a very limiting factor. It 
is therefore very important that solid data are collected as far as possible from every single 
patient enrolled in a study. To this aim, the implementation of SOPs specifically designed for 
paediatric studies and compliance to GCP principles during the entire duration of the clini-
cal trial must be ensured. Proper training must be organized for all the staff involved, and 
constant monitoring of the activities has to be performed. The quality of the data derives also 
from a harmonized method of analysis. This can be achieved for example by the organized 
collection and analysis of samples by a centralized laboratory to rule out instrument’s devia-
tions and ensure standardized results.
Figure 2. DEEP-2 infrastructure. This schematic depicts the set of organizations and human resources employed for the 
conduct of DEEP-2 clinical trial in every country it was performed.
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This issue was properly addressed in the DEEP-2 study. SOPs were set-up and followed for all 
the aspects of the trial. A complex trial infrastructure was arranged in order to fulfil all the GCP 
requirements and promptly respond to all the possible issues and needs arising (Figure 2). This 
infrastructure was made through a well-defined structure of roles and responsibilities for each 
member of the staff.
Laboratories specialized in pharmacokinetics analysis and blood ferritin diagnostics, were 
employed for the centralized assessment of these parameters.
In reference to the centralized evaluation of ferritin analysis, a second laboratory was identified 
within Egypt area due to the impossibility to export biological samples from Egypt which, with 
its three investigation sites (Alexandria, Cairo and Zagazig), retained almost the 40% of the total 
samples collected from patients recruited in the entire study. Consistency of data obtained in the 
two laboratories was ensured using standard controls in both sites for all the analyses performed.
A central laboratory in Australia was assigned for the analysis of images of hepatic R2 and 
cardiac T2* MRIs acquired and transmitted by the investigation sites. The proper calibration 
of MRI machines in every centre was ensured with the use of phantoms delivered to the 
investigation sites.
5. Conclusions
Notwithstanding its important and noble meaning and the possible benefits deriving from its 
successful conclusion for either society and sponsors, the conduction of PCTs is a path under-
mined by obstacles and deterrents. We reported the example of DEEP, a European research 
Project (FP7) coordinated by CVBF and recently concluded. DEEP’s final aim was to produce and 
get the authorization for a new oral liquid formulation of deferiprone with a paediatric indication 
and to extend the information available on deferiprone in iron-overloaded paediatric patients.
Although successfully completed, many issues had to be faced, and deviations from the ini-
tially planned study were the inevitable consequence of the strategies implemented to over-
come them.
The first protocol’s version reported a population’s size of 310 evaluable patients needed for 
getting statistical significance of data. The estimated drop-out rate was 10%, so the calculated 
number of total patients to be recruited was 344. When the study started, it became clear that 
the actual percentage of drop-out was higher, so the protocol had to be amended, and the new 
number of patients to be recruited was increased to 388.
Because of the higher number of patients required, to the initial 15 centres selected for the con-
duct of the study, other 8 centres had to be added to allow the recruitment of the 388 patients 
needed. In actual facts, at the end of the study, 393 patients were randomized, of whom 316 
completed the study.
The enrolment rate of patients at different sites was really heterogeneous. In particular, the 
involvement of two centres respectively in Cairo and Tunis allowed a tremendous number of 
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patients to be recruited because of the high epidemiology of haemoglobinopathies in those 
countries. On the other hand, in other countries like Greece and Italy, the same successful 
recruitment rate was not achieved in the same way; possible explanations are a superior dif-
fusion of the prenatal prevention and the presence of more parallel paediatric studies, which 
have caused a further shrinking of the eligible population.
All the above-mentioned variation to the trial caused an increase in times and costs that were 
not easily accepted by the European Commission who was funding the initial study program: 
while a 20 months’ project extension was agreed, no additional resources were granted. This 
caused a tremendous financial stress to all the 16 private and public partners involved in the 
project (most of them big public hospitals) and only thanks to the contribution from the same 
partners participating to the project, it was possible to efficaciously conclude it. The antici-
pated cost of the overall project increased from 7 to 10 million euros.
The study was supposed to be conducted in 3 years, but it took instead 4.5 years in total, plus 
preliminary activities form PIP submission to study protocol drafting: their duration was sup-
posed to be 1 year long, but it took 3 years instead.
In this chapter, we tried to give the reader a more detailed overview of what obstacles can be 
encountered during the conduction of a paediatric clinical trial and suggested feasible ways 
to deal with them, hoping that this under-developed branch of the pharmaceutical research 
may grow further, providing challenges and opportunities for the next future, and may lead 
to the successful labelling of new treatments for the paediatric population.
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